14th edition

Format
HYBRID

December 2nd & 3rd, 2025

IN-PERSON | STRASBOURG

December 8th ,2025

ONLINE MEETINGS

14th edition

Format
HYBRID

December 2nd & 3rd, 2025

IN-PERSON | STRASBOURG

December 8th ,2025

ONLINE MEETINGS

News

Conference Insight

News /

Conference Insight – Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?

4 Dec 2018 9:30 – 11:00 am

The seed investment market is composed of actors with really diverse degree of specialisation (from totally agnostic and multi-sectorial to pure players in specific therapeutic indications). Do the most specialised funds attract more generalist ones in the financing rounds? What is the respective importance today in the amount of seed investment of the multi-sectorial funds, the 100% healthcare orientated funds and the pure players in the biotech sector.[/vc_column_text][vc_column_text]They will share their experience:

  • Jan Adams, Managing Director, EMBL Ventures (DE)
  • Jonathan Tobin, Investment Director, Arix Bioscience (UK)
Discover the BioFIT 2018 conference programme

Conference Insight Read More »

They will speak at BioFIT 2018!

News /

Discover the new speakers that will share their vision at BioFIT 2018:

Over 70 international experts from academia, industry and biotech will address issues to learn about the latest trends and explore hands-on approaches to tech transfer and open innovation in the field of Life Sciences, by sharing their experience and knowledge.


Alain Chevallier
Life Sciences Partner
Truffle Capital


Marco A. Chacon
Assistant Vice President of Industry Alliances
University of Maryland Baltimore


Rodolphe Besserve
Head SuFT Advisory, Start-up & French Techs
Société Générale Corporate Investments and Banking


Zishan Haroon
Chairman and General Partner
JulzCo

 

Discover all the confirmed speakers
Discover the BioFIT 2018 conference programme

They will speak at BioFIT 2018! Read More »

Apply to the Start-up Slams

News /

Are you an entrepreneur who has created an innovative company (less than 5 years old or to be created)? 

Apply to the presentation sessions to:

  • Promote your innovations
  • Receive a speed-monitoring from pharma, biotech, TTO and investors
  • Find partners who could support your project

 

1. Apply before 30th June
Dedicated to entrepreneurs who have created an innovative company (less than 5 years old or to be created)

2. Be selected
A jury of experts will select the most innovative projects

3. Exhibit
The selected candidates will benefit from a space at BioFIT to hold their one-to-one meetings

4. Pitch
A 6-7 minute presentation of each selected project to potential partners and investors during BioFIT

5. Receive a speed-mentoring
A jury composed of pharma and investors will give feedback and advice to the presenters

6. Be awarded
The most innovative start-up will be awarded by the jury of experts of BioFIT

 

Apply to the Start-up Slams

Apply to the Start-up Slams Read More »

Conference Insight

News /

5 Dec 2018  9:00 – 10:30 am

When addressing the contractual relationships between a university and its spin-off: What are the issues regarding equity, royalties and research income? How do VCs, academic institutions, spin-off management and human resources management of the university interact? What are the main conflicts of interests that can arise from people holding dual positions, in the university and in the start-up?

They will share their experiences:

  • Adrian Ibrahim, Head of technology Transfer, Wellcome Sanger Institute (UK)
  • Caroline Barelle, CEO, Elasmogen (UK)
  • Alain Chevallier, Life Sciences Partner, Truffle Capital (FR)
  • Steven J. Klein, Vice President, Business Development IRICoR – Institute for Research in Immunology and Cancer – Commercialization of Research (CA)
Discover the BioFIT 2018 conference programme

Conference Insight Read More »

We are very honoured to count MSD among the Sponsors of BioFIT 2018

News /

Many thanks to MSD for joining BioFIT 2018 as a Bronze Sponsor!

To make a difference in the lives of people globally through innovative medicines, vaccines, and animal health products. MSD is committed to being the premier, research-intensive biopharmaceutical company and is dedicated to providing leading innovations and solutions for today and the future.

Join this key BioFIT 2018 sponsor to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

We are very honoured to count MSD among the Sponsors of BioFIT 2018 Read More »

Discover the BioFIT 2018 preliminary conference programme!

News /

The BioFIT Steering Committee is glad to announce the BioFIT 2018 preliminary conference programme:

 

PLENARY SESSION: Seed funds crossing borders: How far and how fast is the early-stage investment market in Biotech globalising?

Globalisation of seed investment can be seen as traditionally geographically anchored, now early-stage investors tend to invest in more diversified areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more risk taking, will it change the risk landscape? Isn’t there today an ill-balance between the geographical origin of the investment capacities and the areas where projects needing equity investment are teeming?[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

TRACK 1: Best practices in academia-industry R&D collaborations

  • Artificial Intelligence to speed-up drug discovery: The revolutionary road to advance innovation.
  • A prospective overview of the forthcoming cross-sectorial collaborations and licensing deals between human and animal health
  • Beyond shared means, common strategies to collectively succeed
  • Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances?
Interested in joining a panel?

TRACK 2: Nurturing and licensing early-stage assets

  • What is the right balance between equity, royalties, collaborative research income for the academic institutions in the process of spinning out companies?
  • An overview of the recent joint initiatives to derisk academic-origin assets
  • Questioning TTOs financing models: Could their expected financial outcome bias the tech transfer process?
  • Under pressure: How does the urge to bring rare disease therapies create a new range of business models or collaborative models?
Interested in joining a panel?

TRACK 3: Early-stage innovation: Identify the right funding sources

  • Are philanthropic and alternative sources of soft funding always a free lunch?
  • Shaping your start-up for an industrial exit or an IPO: Are there choices to be made at the very initial stage?
  • Are immunotherapies a new investment Eldorado?
  • Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?
Interested in joining a panel?

Discover the BioFIT 2018 preliminary conference programme! Read More »

Conference insight

News /

Conference insight – Shaping your start-up for an industrial exit or an IPO: Are these choices to be made at the very initial stage?

4 Dec 2018  4:00 – 6:00 pm

Decisions taken at the very initial stage have major consequences for the future development of start-ups with major pitfalls to be avoided. Is it crucial to picture the exit strategy as soon as the company is created? The session relies on its panellists’ stories to go over different approaches of IPO and exits for start-ups.

They will share their experiences:

  • Lucie Ellis, Senior Editor, Pharma Intelligence | Informa (UK) – Moderator
  • Peter Leonardi, CEO, OmniCyte (US)
  • George Hoffman, Co-founder and CEO, Network Immunology (US)
  • Rodolphe Besserve, Head SuFT Advisory, Start-upd & French Techs, Société Générale Corporate Investments and and Banking (FR)
Discover the BioFIT 2018 conference programme

 

Conference insight Read More »

Call for applications

News /

Apply for the presentation sessions! 

> Promote your innovations

> Receive a speed-monitoring from pharma, biotech, TTO and investors

> Find partners who could support your project

Are you an entrepreneur who has created an innovative company (less than 5 years old or to be created)?

Apply for the Start-up Slams!

  1. Apply before 30th June: Dedicated to entrepreneurs who have created an innovative company (less than 5 years old or to be created)
  2. Be selected: A jury of experts will select the most innovative projects
  3. Exhibit: The selected candidates will benefit from a space at BioFIT to hold their one-to-one meetings
  4. Pitch: A 6-7 minute presentation of each selected project to potential partners and investors during bioFIT
  5. Receive a speed-mentoring: A jury composed of pharma and investors will give feeback and advice to the presenters
  6. Be awarded: The most innovative start-up will be awarded by the jury of experts of BioFIT
Apply for the Start-up Slams now

Are you a tech transfer officer with a ready-to-be-licensed technology?

Apply for the Licensing Opportunity Presentations!

  1. Apply: Dedicated to TTO, universities or related structures that have ready-to-be-licensed technologies
  2. Be selected: A jury of experts will select the most innovative technologies
  3. Exhibit: The selected candidates will benefit from a poster’s exhibition at BioFIT describing their out-licensing opportunities
  4. Pitch: Presentations of the selected projects to potential industrial partners during BioFIT
  5. Find partners: The presenters can easily find industrial partners who could in-license their assets
Apply for the Licensing Opportunity Presentations now

Call for applications Read More »

Come hear them speak at BioFIT 2018!

News /

They will speak at BioFIT 2018:

  • Jan Adams, Managing Director, EMBL Ventures (DE)
  • Anjan Aralihalli, Venture Partner, CTI Life Sciences Fund II (CA)
  • Caroline Barelle, CEO, Elasmogen (UK)
  • Yann Barrault, Head of Business Development & Licensing, SATT Grand Centre (FR)
  • Jean-Charles Brosse, Partner Healthcare & Life Sciences, Positive Capital (FR)
  • Alain Chevallier, Life Sciences Partner, Truffle Capital (FR)
  • Lucie Ellis, Senior Editor, Pharma Intelligence | Informa (UK)
  • Juan Garcia, CEO, BioSeed Capital (ES)
  • George Hoffman, Co-founder and CEO, Network Immunology (US)
  • Adrian Ibrahim, Head of Technology Transfer, Wellcome Sanger Institute (UK)
  • Steven J. Klein, Vice President, Business Development, IRICoR – Institute for Research in Immunology and Cancer-Commercialization of Research (CA)
  • Peter Leonardi, CEO, OmniCyte (US)
  • Michael Motz, CBO, NETRIS Pharma (FR)
  • Michael L. Salgaller, Supervisor, Invention Development and Marketing Unit, National Institutes of Health (NIH) | National Cancer Institute (NCI) | Technology Transfer Center (US)
  • Bernd Stowasser, Head of Alliance Management Germany & Global Public Private Partnerships, Sanofi (DE)
  • Jonathan Tobin, Investment Director, Arix Bioscience (UK)
  • Ewa Truchanowicz, Life Sciences Lead, University of Birmingham Enterprise (UK)
  • Bram Vanparys, Investment Director, MS Ventures (NL)
Want to join them?
Discover the conference programme

Come hear them speak at BioFIT 2018! Read More »

With more than 1,200 international actors from 35+ countries, such as big pharma, emerging and small biotech, diagnostic companies, pre-seed / seed / Series A investors, as well as professionals from tech transfer, academia and research institutions, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed, seed and Series A investment rounds in Life Sciences.
Learn more

Organised by:

WITH THE SUPPORT OF:

INSTITUTIONAL PARTNERS:

Keep up to date with the latest news from BioFIT!
Monthly newsletter

"*" indicates required fields

Fullname*
RGPD*
This field is for validation purposes and should be left unchanged.
Contact us!

By phone
+33 (0)3 28 55 90 69

By e-mail

Follow us on LinkedIn

Linkedin
Event venue

Parc des exposition de Strasbourg – Hall 1
Avenue Herrenschmidt, 
67000, Strasbourg, FRANCE

Legal terms
Main Menu

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

WARNING: Some fraudulent companies are supposedly providing the attendees list of BioFIT. And some are passing themselves off as being BioFIT organisation members and asking you to pay. Please note that the BioFIT team will never sell you the BioFIT attendees list and never ask for your bank account details to make you pay for hotel bookings, exhibition fees or others, and certainly not over the phone.Please be extremely vigilant.

Scroll to Top
Cart Have a coupon ?
  • No products in the cart.
Cart - €0.00
  • 0
  • 1